EarningsThe spotlight was on disappointing Skytrofa news on the 2Q24 earnings conference call, overshadowing the interest on Yorvipath's launch.
Market AccessThe delay in getting the earnings conference call started did not help with the disappointing news that Skytrofa, along with the entire growth hormone market, was subject to a broader market access reset lowering the price of growth hormone agents.
Sales GuidanceDespite the increase in sales volume, the lower price of Skytrofa caused ASND to lower their FY24 Skytrofa sales guidance to €220-240M (from €320-340M).